Detalles de la búsqueda
1.
Cervical High-Grade Squamous Intraepithelial Lesion Burden and Standard of Care Treatment Effectiveness and Safety in the United States, 2008-2018: The EACH-WOMAN Project.
J Low Genit Tract Dis
; 27(2): 105-112, 2023 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36815642
2.
Safety and immunogenicity of a modified process hepatitis B vaccine in healthy adults ≥50 years.
Hum Vaccin
; 7(12): 1336-42, 2011 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-22185811
3.
Durability of response to VGX-3100 treatment of HPV16/18 positive cervical HSIL.
Hum Vaccin Immunother
; 17(5): 1288-1293, 2021 05 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33175656
4.
Safety and immunogenicity of VGX-3100 formulations in a healthy young adult population.
Hum Vaccin Immunother
; 16(6): 1404-1412, 2020 06 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31860383
5.
Safety, tolerability and immunogenicity of a recombinant hepatitis B vaccine manufactured by a modified process in healthy young adults.
Hum Vaccin
; 5(2): 92-7, 2009 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-18690015
6.
Safety and immunogenicity of a recombinant hepatitis B vaccine manufactured by a modified process in renal pre-dialysis and dialysis patients.
Vaccine
; 32(48): 6521-6, 2014 Nov 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-25252192
7.
Safety and immunogenicity of a modified process hepatitis B vaccine in healthy neonates.
Vaccine
; 30(8): 1476-80, 2012 Feb 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-22227229
8.
Immunogenicity and safety of a Haemophilus influenzae B (Hib)-hepatitis B vaccine with a modified process hepatitis B component administered with concomitant pneumococcal conjugate vaccine to infants.
Vaccine
; 29(45): 7942-8, 2011 Oct 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-21875633
9.
Safety and immunogenicity of a modified process hepatitis B vaccine in healthy infants.
Pediatr Infect Dis J
; 30(7): e109-13, 2011 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-21552183
10.
Safety and immunogenicity of three different formulations of a liquid hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine at 2, 4, 6 and 12-14 months of age.
Vaccine
; 29(6): 1324-31, 2011 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-21134456
11.
A randomized, multicenter, open-label clinical trial to assess the anamnestic immune response 4 to 8 years after a primary hepatitis B vaccination series.
Pediatr Infect Dis J
; 29(10): 972-4, 2010 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-20724955
12.
Safety and immunogenicity of a hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine at 2, 3, 4, and 12-14 months of age.
Vaccine
; 27(19): 2540-7, 2009 Apr 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-19124057
13.
Short interfering RNA-mediated inhibition of herpes simplex virus type 1 gene expression and function during infection of human keratinocytes.
J Virol
; 78(19): 10276-81, 2004 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-15367593
Resultados
1 -
13
de 13
1
Próxima >
>>